UNLABELLED: 7 BACKGROUND: No generally agreed-upon method is available for predicting the prognosis of salivary gland cancers. RB1-inducible coiled-coil 1 (RB1CC1) is a positive regulator for the retinoblastoma tumor suppressor (RB1) pathway, and is a suitable marker for evaluating the clinical course of breast cancer. We investigated whether RB1CC1 predicts the prognosis of salivary gland cancers. METHODS: Molecules involved in the RB1CC1 pathway, including RB1CC1, RB1, p53, and Ki-67, were evaluated immunohistochemically in 36 cases of salivary gland cancers. The relationships between clinicopathologic features and disease-free-survival intervals were analyzed by a Kaplan-Meier log-rank test and a multivariate Cox proportional hazard regression. RESULTS: Nuclear RB1CC1 loss in the tumors was significantly associated with a worse disease-free survival (log-rank test, chi-square value = 11.644, p = .0006), and was the maximum critical risk (multivariate Cox proportional hazard ratio = 11.112, 95% confidence interval [CI] = 1.776-69.510, p = .0100). CONCLUSIONS: Nuclear expression of RB1CC1 predicts a better clinical outcome and is useful in the follow-up of salivary gland cancers.
UNLABELLED: 7 BACKGROUND: No generally agreed-upon method is available for predicting the prognosis of salivary gland cancers. RB1-inducible coiled-coil 1 (RB1CC1) is a positive regulator for the retinoblastoma tumor suppressor (RB1) pathway, and is a suitable marker for evaluating the clinical course of breast cancer. We investigated whether RB1CC1 predicts the prognosis of salivary gland cancers. METHODS: Molecules involved in the RB1CC1 pathway, including RB1CC1, RB1, p53, and Ki-67, were evaluated immunohistochemically in 36 cases of salivary gland cancers. The relationships between clinicopathologic features and disease-free-survival intervals were analyzed by a Kaplan-Meier log-rank test and a multivariate Cox proportional hazard regression. RESULTS: Nuclear RB1CC1 loss in the tumors was significantly associated with a worse disease-free survival (log-rank test, chi-square value = 11.644, p = .0006), and was the maximum critical risk (multivariate Cox proportional hazard ratio = 11.112, 95% confidence interval [CI] = 1.776-69.510, p = .0100). CONCLUSIONS: Nuclear expression of RB1CC1 predicts a better clinical outcome and is useful in the follow-up of salivary gland cancers.
Authors: Michael J Kerins; Pengfei Liu; Wang Tian; William Mannheim; Donna D Zhang; Aikseng Ooi Journal: Mol Cell Biol Date: 2019-06-13 Impact factor: 4.272